DRIO DarioHealth (DRIO) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001533998
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
11
13F, latest reported quarter
What the filings say about DRIO
Insiders, 180 days
+$100.0K net bought
1 buyer
DarioHealth insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, DarioHealth Corp. insiders bought a net $100.0K of stock across 36 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 33.5% of the 43,026 shares held after it.
- No other insider bought within 30 days.
- 11 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Matheis Dennis bought about $100.0K of DRIO on Jul 23, 2026, the largest insider purchase at the company on our record; 11 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 buys), the last on Nov 12, 2024.
- -13.6% median (-13.4% mean) 90-day return after 11 previous buys.
- The trade is 42.1% of the 95,000 shares held after it.
- No other insider bought within 30 days.
- 11 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CCO Nelson Steven Charles bought about $21.2K of DRIO on Aug 27, 2025, the largest insider purchase at the company on our record; 11 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (10 buys), the last on Sep 11, 2024.
- -13.3% median (-12.2% mean) 90-day return after 10 previous buys.
- The trade is 9.1% of the 55,000 shares held after it.
- No other insider bought within 30 days.
- 11 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Nelson Steven Charles bought about $4.5K of DRIO on Nov 12, 2024; 11 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Sep 10, 2024.
- -13.6% median (-12.4% mean) 90-day return after 9 previous buys.
- The trade is 10.0% of the 50,000 shares held after it.
- 1 other insider bought within 30 days.
- 11 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Nelson Steven Charles bought about $4.0K of DRIO on Sep 11, 2024; 1 other insider bought within 30 days and 11 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Sep 9, 2024.
- -13.7% median (-12.2% mean) 90-day return after 8 previous buys.
- The trade is 11.1% of the 45,000 shares held after it.
- 1 other insider bought within 30 days.
- 11 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Nelson Steven Charles bought about $4.2K of DRIO on Sep 10, 2024; 1 other insider bought within 30 days and 11 funds added in the latest 13F quarter.36 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$100.0K over 180 days
more than 72% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
11 funds bought in last quarter
below 83% of Medical Devices
Revenue
-17.3% year over year
below 89% of Medical Devices
Margin
-186.6% net margin
below 84% of Medical Devices
Buybacks
no share repurchases reported
Short interest
1.2% of the float short (float per yahoo 2026-10-26) · 4.4 days to cover · settled 2026-09-30
below 74% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch DRIO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-77.4%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns DRIO: institutional holders (13F)
13F holdings, latest reported quarter
1,221,382 sh
$8.1M
65,675 sh
$433.5K
58,035 sh
$383.3K
37,796 sh
$249.5K
37,387 sh
$246.8K
Congress trades in DRIO
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
DRIO planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
DRIO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$119.8K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$7.6K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$279.8K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$433.5K position · as of 2026-06-30
0.0%
Dimensional US Sustainability Core 1 ETF
$5.4K position · as of 2026-07-31
0.0%
Fidelity Series Total Market Index Fund
$69.2K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $100.0K bought by insiders over 180 days, 11 funds added last quarter. Each figure is a federal filing, dated the day it went public.
DRIO financials
Revenue growth
-17.3%
XBRL, annual
Net margin
-186.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$21.0M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM DRIO
| FY Dec 2025 | $22.4M |
| FY Dec 2024 | $27.0M |
| FY Dec 2023 | $20.4M |
| FY Dec 2022 | $27.7M |
| FY Dec 2021 | $20.5M |
| Jun 2026 | $5.2M |
| Mar 2026 | $5.6M |
| Dec 2025 | $5.2M |
| Sep 2025 | $5.0M |
| Jun 2025 | $5.4M |
| Mar 2025 | $6.8M |
| Dec 2024 | $7.6M |
| Sep 2024 | $7.4M |
At each fiscal year end
Single quarter
Net margin, TTM
-169.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM DRIO
| FY Dec 2025 | -186.6% |
| FY Dec 2024 | -158.1% |
| FY Dec 2023 | -292.0% |
| FY Dec 2022 | -224.9% |
| FY Dec 2021 | -374.2% |
| Jun 2026 | -153.1% |
| Mar 2026 | -147.7% |
| Dec 2025 | -172.6% |
| Sep 2025 | -209.0% |
| Jun 2025 | -241.9% |
| Mar 2025 | -136.7% |
| Dec 2024 | -126.7% |
| Sep 2024 | -166.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$25.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM DRIO
| FY Dec 2025 | -$26.1M |
| FY Dec 2024 | -$38.7M |
| FY Dec 2023 | -$31.0M |
| FY Dec 2022 | -$48.3M |
| FY Dec 2021 | -$50.7M |
| Jun 2026 | -$6.1M |
| Mar 2026 | -$6.1M |
| Dec 2025 | -$5.9M |
| Sep 2025 | -$7.4M |
| Jun 2025 | -$6.1M |
| Mar 2025 | -$6.7M |
| Dec 2024 | -$6.8M |
| Sep 2024 | -$7.4M |
At each fiscal year end
Single quarter
Debt to equity
0.75x
long-term 2026-06-30 plus current 2025-03-31 (15 months older than the period end); equity 2026-06-30
Debt to equity DRIO
| FY Dec 2025 | 0.60x |
| FY Dec 2024 | 0.40x |
| FY Dec 2023 | 0.49x |
| FY Dec 2022 | 0.34x |
| FY Dec 2021 | 0.00x |
| Jun 2026 | 0.75x |
| Mar 2026 | 0.66x |
| Dec 2025 | 0.60x |
| Sep 2025 | 0.55x |
| Jun 2025 | 0.64x |
| Mar 2025 | 0.40x |
| Dec 2024 | 0.40x |
| Sep 2024 | 0.49x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.61x
TTM operating cash flow over long-term 2026-06-30 plus current 2025-03-31 (15 months older than the period end)
Cash flow to debt DRIO
| FY Dec 2025 | -0.63x |
| FY Dec 2024 | -1.33x |
| FY Dec 2023 | -1.06x |
| FY Dec 2022 | -1.78x |
| FY Dec 2021 | n/a |
| Jun 2026 | -0.61x |
| Mar 2026 | -0.61x |
| Dec 2025 | -0.63x |
| Sep 2025 | -0.65x |
| Jun 2025 | -0.66x |
| Mar 2025 | -1.10x |
| Dec 2024 | -1.33x |
| Sep 2024 | -1.36x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-59.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity DRIO
| FY Dec 2025 | -59.6% |
| FY Dec 2024 | -65.7% |
| FY Dec 2023 | -86.0% |
| FY Dec 2022 | -75.1% |
| FY Dec 2021 | -135.0% |
| Jun 2026 | -59.9% |
| Mar 2026 | -59.9% |
| Dec 2025 | -59.6% |
| Sep 2025 | -63.4% |
| Jun 2025 | -66.9% |
| Mar 2025 | -59.1% |
| Dec 2024 | -65.7% |
| Sep 2024 | -74.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-34.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets DRIO
| FY Dec 2025 | -36.4% |
| FY Dec 2024 | -39.7% |
| FY Dec 2023 | -55.1% |
| FY Dec 2022 | -56.5% |
| FY Dec 2021 | -112.7% |
| Jun 2026 | -34.8% |
| Mar 2026 | -37.2% |
| Dec 2025 | -36.4% |
| Sep 2025 | -37.2% |
| Jun 2025 | -38.3% |
| Mar 2025 | -35.5% |
| Dec 2024 | -39.7% |
| Sep 2024 | -43.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital DRIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-34.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed DRIO
| FY Dec 2025 | -36.1% |
| FY Dec 2024 | -62.0% |
| FY Dec 2023 | -61.2% |
| FY Dec 2022 | -61.0% |
| FY Dec 2021 | -133.3% |
| Jun 2026 | -34.3% |
| Mar 2026 | -36.3% |
| Dec 2025 | -36.1% |
| Sep 2025 | -39.8% |
| Jun 2025 | -41.6% |
| Mar 2025 | -45.7% |
| Dec 2024 | -62.0% |
| Sep 2024 | -63.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
0.55x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing DRIO
| FY Dec 2025 | 1.09x |
| FY Dec 2024 | 2.22x |
| FY Dec 2023 | 17.82x |
| FY Dec 2022 | 32.42x |
| FY Dec 2021 | 62.06x |
| Jun 2026 | 1.08x |
| Mar 2026 | 0.91x |
| Dec 2025 | 1.09x |
| Sep 2025 | 1.54x |
| Jun 2025 | 1.01x |
| Mar 2025 | 1.26x |
| Dec 2024 | 2.22x |
| Sep 2024 | 4.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$68.0M
market value at close 2026-10-26 on 2026-08-11 shares, plus long-term 2026-06-30 plus current 2025-03-31 (15 months older than the period end), minus cash 2026-06-30
Enterprise value DRIO
| FY Dec 2025 | $96.3M |
| FY Dec 2024 | $537.2M |
| FY Dec 2023 | $927.9M |
| FY Dec 2022 | $2.0B |
| FY Dec 2021 | $4.3B |
| Jun 2026 | $83.0M |
| Mar 2026 | $84.8M |
| Dec 2025 | $96.3M |
| Sep 2025 | $798.4M |
| Jun 2025 | $607.8M |
| Mar 2025 | $510.1M |
| Dec 2024 | $537.2M |
| Sep 2024 | $685.9M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-76.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield DRIO
| FY Dec 2025 | -33.9% |
| FY Dec 2024 | -7.2% |
| FY Dec 2023 | -3.3% |
| FY Dec 2022 | -2.4% |
| FY Dec 2021 | -1.2% |
| Jun 2026 | -52.8% |
| Mar 2026 | -43.4% |
| Dec 2025 | -33.9% |
| Sep 2025 | -3.4% |
| Jun 2025 | -4.6% |
| Mar 2025 | -6.3% |
| Dec 2024 | -7.2% |
| Sep 2024 | -5.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -54%, PEG needs growth
PEG, trailing DRIO
| FY Dec 2025 | 0.02x |
| FY Dec 2024 | 0.01x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | 0.02x |
| Sep 2025 | 0.02x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.01x |
| Sep 2024 | 0.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $22.4M | $27.0M | $20.4M | $27.7M |
| Gross profit | $12.7M | $13.3M | $6.0M | $9.7M |
| Operating income | -$36.7M | -$57.7M | -$56.2M | -$56.8M |
| Net income | -$41.7M | -$42.7M | -$59.4M | -$62.2M |
| EPS (diluted) | 10.12 | 12.27 | 1.93 | 2.54 |
| Operating cash flow | -$25.9M | -$38.6M | -$30.4M | -$47.8M |
| Cash | $21.8M | $27.8M | $36.8M | $49.4M |
| Long-term debt | $30.7M | $23.5M | $24.6M | $18.1M |
| Buybacks | n/a | n/a | n/a | $134.0K |
SEC XBRL, fiscal years, as known on 2026-10-28
DRIO Stock Sonar score 6/7 axes
Find similar shapesCompareDRIO ranks highest on insider conviction (62nd percentile) and risk and compliance (41st), and lowest on growth (11th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
DRIO filings, in plain words
Are DarioHealth insiders buying or selling DRIO?
In the 180 days to 2026-10-28, DarioHealth insiders were net buyers, a net $100.0K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, DarioHealth insiders were net buyers of DRIO, a net $100.0K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
